Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: Trial protocol and 18 months results
Erişim
info:eu-repo/semantics/closedAccessTarih
2022Yazar
de la Rosette, Jean J. M. C. H.Martov, Alexeyb
Hurle, Rodolfo
Favre, Gabriel
Mamoulakis, Charalampos
Castanheira de Oliveira, Manuel
Stenzl, Arnulf
Linares-Espinós, Estefania
Trelles Guzmán, Carlos R.
Gravas, Stavros
Knoll, Thomas
Boz, Mustafa Yücel
Herrmann, Thomas
del Pilar Laguna Pes, Maria
Üst veri
Tüm öğe kaydını gösterKünye
de la Rosette, J. J. M. C. H., Martov, A., Hurle, R., Favre, G., Mamoulakis, C., Castanheira de Oliveira, M. ... del Pilar Laguna Pes, M. (2022). Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: Trial protocol and 18 months results. World Journal of Urology, 40(3), 727-738. https://doi.org/10.1007/s00345-021-03866-4Özet
Purpose White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance. Methods Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses. Results 689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data. Conclusion There was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients. Registration ClinicalTrials.gov Identifier NCT02252549 (30-09-2014).
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
World Journal of UrologyCilt
40Sayı
3Koleksiyonlar
- Makale Koleksiyonu [3701]
- Makale Koleksiyonu [340]
- PubMed İndeksli Yayınlar Koleksiyonu [4120]
- Scopus İndeksli Yayınlar Koleksiyonu [6404]
- WoS İndeksli Yayınlar Koleksiyonu [6516]